HZHuasu Zeng

Huasu Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huasu Zeng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Cancer History on Clinical Outcomes Among Patients Without Standard Modifiable Cardiovascular Risk Factors Who Received PCI

    by Min Wang, Qizhi Chen, Huasu Zeng, Lin Gao, Mingxing Wu, Junfeng Zhang, Zhengde Tang, Jun Gu, Changqian Wang

    Background: Coronary artery disease (CAD) has traditionally been attributed to a cluster of standard modifiable cardiovascular risk factors (SMuRFs), including hypertension, diabetes, dyslipidemia, and smoking. Among SMuRF‐less patients (those with none of the four SMuRFs), cancer emerges as an increasingly recognized nontraditional risk factor. Objective: The purpose of this study was to evaluate the influence of coexisting cancer on the clinical outcomes among SMuRF‐less patients who underwent percutaneous coronary intervention (PCI). Methods: This single‐center prospective cohort study enrolled 1416 SMuRF‐less CAD patients from August 2016 to December 2024; 493 who received PCI with stents were included, and 468 were analyzed after exclusions (67 with cancer, 401 without). The primary outcome was the incidence of major adverse cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction (MI), heart failure hospitalization, and nonfatal stroke. The secondary outcome was all‐cause mortality. Results: After a median follow‐up of 46 months, the cancer group showed poorer prognosis than the noncancer group in terms of MACEs (25.37 vs. 10.97%; HR, 2.828; 95% CI, 1.614–4.957; p < 0.001) and all‐cause mortality (13.43 vs. 3.49%; HR, 4.078; 95% CI, 1.764–9.427; p < 0.001). Moreover, proportional hazards analyses identified cancer history as an independent predictor for MACEs (HR 3.40, 95% CI 1.73–6.68, p < 0.001) and all‐cause mortality (HR 5.44, 95% CI 2.14–13.84, p < 0.001) following coronary stent implantation. In addition, serum C‐reactive protein (CRP) levels were significantly higher in the cancer group than in the noncancer group, and we determined the optimal cutoff value of CRP as 1.25 mg/L. Kaplan–Meier analysis showed that the high CRP group had lower MACE‐free survival than that of the low CRP group ( p = 0.030) in cancer subgroup analyses. Among the cancer group, patients who were presented as having current cancer had more MACE events than those who were presented as having past cancer at the time of PCI (HR 3.60, 95% CI 1.28–10.13, p = 0.015). Conclusion: Cancer history was a potent, independent predictor of poorer prognosis in SMuRF‐less CAD patients following PCI. Routine measurement of CRP may help identify cancer patients at highest risk.

  • Open Access

    Uric Acid-Lowering Therapy with Febuxostat in Patients with Chronic Heart Failure and Hyperuricemia: A Prospective and Observational Cohort Study

    by Jiahan Ke, Xiaohan Qiu, Min Wang, Huasu Zeng, Changqian Wang, Junfeng Zhang, Huafang Zhu, Jun Gu

    Hyperuricemia is associated with poor clinical outcomes in several cardiovascular diseases, including heart failure (HF). However, whether lowering serum uric acid (SUA) levels improves the prognosis of HF remains insufficiently studied. To evaluate whether urate-lowering therapy (ULT) with febuxostat confers clinical benefits in patients with HF and concomitant hyperuricemia. Prospective, observational cohort study. Patients with chronic HF and hyperuricemia were enrolled and assigned either to a febuxostat group or to a non-ULT group and were followed prospectively for 5 years. The primary endpoint was all-cause mortality or rehospitalization for HF. Among 2005 patients, those with higher SUA levels experienced more endpoint events. After propensity score matching, we found that febuxostat therapy significantly reduced the incidence of primary endpoints in patients with HFwith preserved ejection fraction (HFpEF) [p = 0.012; hazard ratios (HR), 0.744; 95% confidence intervals (CI), 0.589-0.939], but not in those with HF with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) (p = 0.234; HR, 0.894; 95% CI, 0.742-1.077). The benefits of febuxostat in HFpEF were most evident in patients within the highest tertiles of B-type natriuretic peptide (BNP) (p = 0.021; HR, 0.647; 95% CI, 0.436-0.960) and SUA (p = 0.025; HR, 0.651; 95% CI, 0.441-0.963). High SUA levels are associated with increased all-cause mortality and rehospitalization for HF. Febuxostat-mediated SUA reduction significantly improved clinical outcomes in patients with HFpEF, particularly those with elevated SUA and BNP levels.


  • Open Access

    Preventive Effect of Shenfu Injection on Arrhythmia After Percutaneous Coronary Intervention in Patients With ST‐Segment Elevation Myocardial Infarction: A Prospective Randomized Controlled Trial

    by Xiaohan Qiu, Yue Wang, Jiahan Ke, Min Wang, Huasu Zeng, Huafang Zhu, Jun Gu

    Background and Aims: Arrhythmias and major adverse cardiac events remain significant complications following ST‐segment elevation myocardial infarction (STEMI). Shenfu injection, a traditional Chinese medicine formulation, has shown cardioprotective effects in preclinical studies. This trial is aimed at investigating whether Shenfu injection as an adjunctive therapy to standard treatment could reduce arrhythmias and improve clinical outcomes in patients with STEMI undergoing percutaneous coronary intervention (PCI). Methods: A single‐center, prospective, randomized, controlled trial was conducted at Shanghai Ninth People′s Hospital among 245 patients with STEMI undergoing PCI. Participants were randomized to receive either standard therapy plus Shenfu injection (50 mL, administered intravenously twice daily for five consecutive days) ( n = 123) or standard therapy alone ( n = 122). The primary endpoint was the incidence of in‐hospital arrhythmias. Secondary endpoints included major adverse cardiac events (MACEs) during the 12‐month follow‐up period and cardiac magnetic resonance imaging parameters. Results: A total of 245 patients underwent randomization (123 assigned to Shenfu injection group and 122 assigned to control group). During hospitalization, patients assigned to Shenfu injection had a significantly lower incidence of arrhythmias compared with the control group (24.4% vs. 38.5%, p = 0.017), with the most pronounced effect on frequent ventricular premature contractions (7.3% vs. 15.5%, p = 0.042). After adjustment for key baseline covariates including age, coronary artery disease extent, myocardial injury markers (CK‐MB max and TNI max), left ventricular ejection fraction, B‐type natriuretic peptide, door‐to‐balloon time, hypertension, and diabetes mellitus, Shenfu injection remained independently associated with reduced risk of in‐hospital arrhythmias (adjusted OR 0.454, 95% CI: 0.249–0.827, p = 0.010). Cardiac magnetic resonance imaging performed in 174 patients revealed significantly smaller infarct size (16.1 ± 9.1 vs. 20.8 ± 13.1 g, p = 0.007) and lower incidence of microvascular obstruction (45.0% vs. 65.0%, p = 0.008) in the Shenfu group, with both parameters showing significant positive correlations with arrhythmia occurrence. During the 12‐month follow‐up, patients receiving Shenfu injection had a higher event‐free rate from MACEs compared with the control group (12‐month Kaplan‐Meier event‐free rate estimates, 84.6% vs. 73.0%, respectively; p = 0.028). Conclusions: Treatment with Shenfu injection as an adjunctive therapy to standard treatment in patients with STEMI undergoing PCI significantly reduced in‐hospital arrhythmias, infarct size, microvascular obstruction, and major adverse cardiac events during a 12‐month follow‐up period. The independent effect on arrhythmias after comprehensive statistical adjustment and the demonstrated correlation between reduced myocardial damage and arrhythmia prevention suggest the potential therapeutic value of Shenfu injection in improving both short‐term and long‐term outcomes in STEMI patients. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200066918


  • Effect of lgals3a on embryo development of zebrafish

    by Kan Chen, Yuqi Fan, Jun Gu, Zhihua Han, Yue Wang, Lin Gao, Huasu Zeng, Chengyu Mao, Changqian Wang

    Our study was aimed to investigate the effects of lgals3a (Gal-3 encoding gene) on the development of zebrafish embryo and its underlying mechanisms. Morpholino (MO) technology was used to inhibit the expression of zebrafish lgals3a, and the effect of lgals3a gene knockdown on zebrafish embryo development and the number of monocyte macrophages was observed. Effect of lgals3a-e3i3-MO on apoptosis of zebrafish was detected by acridine orange staining. In addition, the mRNA expression levels of Wnt/β-catenin signaling pathway-related genes were detected by RT-qPCR. Compared with control-MO group, the zebrafish embryos injected with lgals3a-e3i3-MO had obvious defects in the head, eyes, and tail, and pericardial edema. Lgals3a-e3i3-MO significantly reduced the number of mononuclear macrophages in zebrafish embryos compared with the control-MO group. The results of acridine orange staining showed that compared with the control-MO group, lgals3a-e3i3-MO promoted cardiomyocyte apoptosis in zebrafish. Furthermore, lgals3a-e3i3-MO significantly up-regulated the expression of dkk1b, wnt9a, lrp5, fzd7a, β-catenin, Gsk-3β, mycn, myca in the Wnt/β-catenin pathway, and decreased the expression of lef1. These results indicate that lgals3a-e3i3-MO inhibits zebrafish embryo development, reduces the number of mononuclear macrophages, activates Wnt/β-catenin signaling pathway and promotes cardiomyocyte apoptosis.


  • Open Access

    Balloon Deflation Strategy during Primary Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Clinical Trial and Numerical Simulation-Based Analysis

    by Jun Gu, Yang Zhuo, Tian-Jiao Liu, Jie Li, Zhao-Fang Yin, Zuo-Jun Xu, Li Fan, Qing He, Kan Chen, Hua-Su Zeng, et al.

    Background. Primary percutaneous coronary intervention (PCI) is the best available reperfusion strategy in patients with acute ST-segment elevation myocardial infarction (STEMI). However, PCI is associated with a serious problem known as no-reflow phenomenon, resulting in poor clinical and functional outcomes. This study aimed to compare the influences of different balloon deflation velocity on coronary flow and cardiovascular events during primary PCI in STEM as well as transient hemodynamic changes in in vitro experiments.Method and Results. 211 STEMI patients were randomly assigned to either a rapid or a slow balloon deflation group during stent deployment. The primary end point was coronary flow at the end of PCI procedure, and secondary end points included myocardial infarct size. Transient hemodynamic changes were evaluated through an in vitro experimental apparatus and a computer model. In clinical practice, the level of corrected TIMI frame count (cTFC) in slow balloon deflation after primary PCI was significantly lower than that of rapid balloon deflation, which was associated with smaller infarct size. Numerical simulations revealed that the rapid deflation led to a sharp acceleration of flow in the balloon-vessel gap and a concomitant abnormal rise in wall shear stress (WSS).Conclusion. This randomized study demonstrated that the slow balloon deflation during stent implantation improved coronary flow and reduced infarct size in reperfused STEMI. The change of flow in the balloon-vessel gap and WSS resulted from different balloon deflation velocity might be partly accounted for this results.